The contraceptive vaginal ring (NuvaRing®) and hemostasis: A comparative study

E. M. Magnusdóttir; R. I. Bjarnadóttir; P. T. Önundarson; B. R. Gudmundsdóttir; R. T. Geirsson; S. D. Magnusdóttir; Th O.M. Dieben; Brynja R Guðmundsdóttir

doi:10.1016/j.contraception.2003.12.010

The contraceptive vaginal ring (NuvaRing®) and hemostasis: A comparative study

E. M. Magnusdóttir
, R. I. Bjarnadóttir
, P. T. Önundarson
, B. R. Gudmundsdóttir
, R. T. Geirsson
, S. D. Magnusdóttir
, Th O.M. Dieben
, Brynja R Guðmundsdóttir

University of Iceland, Landspitali

Research output: Contribution to journal › Article › peer-review

Abstract

This open-label, nonrandomized study compared changes in hemostatic variables during NuvaRing® and oral levonorgestrel 150 μg/ ethinylestradiol 30 μg (LNG/EE) use for six cycles. Eighty-seven women started the study, 44 with NuvaRing and 43 with the LNG/EE oral contraceptive. For most procoagulation variables, there was no difference between NuvaRing and oral LNG/EE; only Factor VII levels increased in the NuvaRing group and decreased in the LNG/EE group. The majority of assessed variables show that anticoagulation and fibrinolytic activity was comparable between the NuvaRing and oral LNG/EE groups. Antithrombin activity and protein C activity both tended to be higher with NuvaRing. Levels of tissue plasminogen activator decreased in both groups but the reduction was smaller with NuvaRing. There were no significant differences in fibrin turnover between the treatment groups. The data show that both NuvaRing and oral LNG/EE are associated with a minimal effect on hemostatic variables.

Original language	English
Pages (from-to)	461-467
Number of pages	7
Journal	Contraception
Volume	69
Issue number	6
DOIs	https://doi.org/10.1016/j.contraception.2003.12.010
Publication status	Published - Jun 2004

Bibliographical note

Funding Information: This study was supported by NV Organon, Oss, The Netherlands. We are very grateful to K.A. Einarsdóttir and L. Bergman in the Coagulation Laboratory of the Hematology Department for their valuable help with the assays, and to K. Siguróardóttir for her participation in the clinical procedures. We are most grateful to E. van der Meulen for help with the statistical analysis.

Other keywords

Coagulation
Fibrinolysis
Hemostasis
NuvaRing
Oral contraceptives

Access to Document

10.1016/j.contraception.2003.12.010

Cite this

@article{c287b2fe1eb647dda4691c00589232be,

title = "The contraceptive vaginal ring (NuvaRing{\textregistered}) and hemostasis: A comparative study",

abstract = "This open-label, nonrandomized study compared changes in hemostatic variables during NuvaRing{\textregistered} and oral levonorgestrel 150 μg/ ethinylestradiol 30 μg (LNG/EE) use for six cycles. Eighty-seven women started the study, 44 with NuvaRing and 43 with the LNG/EE oral contraceptive. For most procoagulation variables, there was no difference between NuvaRing and oral LNG/EE; only Factor VII levels increased in the NuvaRing group and decreased in the LNG/EE group. The majority of assessed variables show that anticoagulation and fibrinolytic activity was comparable between the NuvaRing and oral LNG/EE groups. Antithrombin activity and protein C activity both tended to be higher with NuvaRing. Levels of tissue plasminogen activator decreased in both groups but the reduction was smaller with NuvaRing. There were no significant differences in fibrin turnover between the treatment groups. The data show that both NuvaRing and oral LNG/EE are associated with a minimal effect on hemostatic variables.",

keywords = "Coagulation, Fibrinolysis, Hemostasis, NuvaRing, Oral contraceptives",

author = "Magnusd{\'o}ttir, \{E. M.\} and Bjarnad{\'o}ttir, \{R. I.\} and {\"O}nundarson, \{P. T.\} and Gudmundsd{\'o}ttir, \{B. R.\} and Geirsson, \{R. T.\} and Magnusd{\'o}ttir, \{S. D.\} and Dieben, \{Th O.M.\} and Gu{\dh}mundsd{\'o}ttir, \{Brynja R\}",

note = "Funding Information: This study was supported by NV Organon, Oss, The Netherlands. We are very grateful to K.A. Einarsd{\'o}ttir and L. Bergman in the Coagulation Laboratory of the Hematology Department for their valuable help with the assays, and to K. Sigur{\'o}ard{\'o}ttir for her participation in the clinical procedures. We are most grateful to E. van der Meulen for help with the statistical analysis.",

year = "2004",

month = jun,

doi = "10.1016/j.contraception.2003.12.010",

language = "English",

volume = "69",

pages = "461--467",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - The contraceptive vaginal ring (NuvaRing®) and hemostasis

T2 - A comparative study

AU - Magnusdóttir, E. M.

AU - Bjarnadóttir, R. I.

AU - Önundarson, P. T.

AU - Gudmundsdóttir, B. R.

AU - Geirsson, R. T.

AU - Magnusdóttir, S. D.

AU - Dieben, Th O.M.

AU - Guðmundsdóttir, Brynja R

N1 - Funding Information: This study was supported by NV Organon, Oss, The Netherlands. We are very grateful to K.A. Einarsdóttir and L. Bergman in the Coagulation Laboratory of the Hematology Department for their valuable help with the assays, and to K. Siguróardóttir for her participation in the clinical procedures. We are most grateful to E. van der Meulen for help with the statistical analysis.

PY - 2004/6

Y1 - 2004/6

N2 - This open-label, nonrandomized study compared changes in hemostatic variables during NuvaRing® and oral levonorgestrel 150 μg/ ethinylestradiol 30 μg (LNG/EE) use for six cycles. Eighty-seven women started the study, 44 with NuvaRing and 43 with the LNG/EE oral contraceptive. For most procoagulation variables, there was no difference between NuvaRing and oral LNG/EE; only Factor VII levels increased in the NuvaRing group and decreased in the LNG/EE group. The majority of assessed variables show that anticoagulation and fibrinolytic activity was comparable between the NuvaRing and oral LNG/EE groups. Antithrombin activity and protein C activity both tended to be higher with NuvaRing. Levels of tissue plasminogen activator decreased in both groups but the reduction was smaller with NuvaRing. There were no significant differences in fibrin turnover between the treatment groups. The data show that both NuvaRing and oral LNG/EE are associated with a minimal effect on hemostatic variables.

AB - This open-label, nonrandomized study compared changes in hemostatic variables during NuvaRing® and oral levonorgestrel 150 μg/ ethinylestradiol 30 μg (LNG/EE) use for six cycles. Eighty-seven women started the study, 44 with NuvaRing and 43 with the LNG/EE oral contraceptive. For most procoagulation variables, there was no difference between NuvaRing and oral LNG/EE; only Factor VII levels increased in the NuvaRing group and decreased in the LNG/EE group. The majority of assessed variables show that anticoagulation and fibrinolytic activity was comparable between the NuvaRing and oral LNG/EE groups. Antithrombin activity and protein C activity both tended to be higher with NuvaRing. Levels of tissue plasminogen activator decreased in both groups but the reduction was smaller with NuvaRing. There were no significant differences in fibrin turnover between the treatment groups. The data show that both NuvaRing and oral LNG/EE are associated with a minimal effect on hemostatic variables.

KW - Coagulation

KW - Fibrinolysis

KW - Hemostasis

KW - NuvaRing

KW - Oral contraceptives

UR - https://www.scopus.com/pages/publications/2442430703

U2 - 10.1016/j.contraception.2003.12.010

DO - 10.1016/j.contraception.2003.12.010

M3 - Article

C2 - 15157790

SN - 0010-7824

VL - 69

SP - 461

EP - 467

JO - Contraception

JF - Contraception

IS - 6

ER -

The contraceptive vaginal ring (NuvaRing®) and hemostasis: A comparative study

Abstract

Bibliographical note

Other keywords

Access to Document

Fingerprint

Cite this